No Means No: Genzyme Responds To Sanofi's Hostile Bid

Sanofi CEO Viehbacher indicated a price of $69- to $80-per-share would be acceptable, Genzyme reveals in an SEC filing.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet